Panel A shows William J. Harrington (1924 Harrington ( -1992 . Panel B shows rapid development of thrombocytopenia, followed by a return to normal platelet levels, in healthy volunteers who received plasma from patients with idiopathic thrombocytopenic purpura (from Harrington et al.
1 ).
they have the genetic marks of antibodies made in response to a persistent antigenic stimulus, but what drives the process is unknown. 3 The Fc region of the IgG antibodies on the surface of the platelet in patients with ITP binds to Fcγ receptors displayed by macrophages. This encounter triggers the phagocytosis of an anti bodycoated platelet by a macrophage. In the pres ence of highaffinity IgG antiplatelet autoanti bodies, the lifespan of a platelet that enters the blood is only a few hours, whereas normally, the lifespan is 10 days. Thrombocytopenia occurs because the rapid rate of destruction exceeds the rate of production of platelets by megakaryocytes in the marrow. Most of the macrophages that in gest antibodycoated platelets reside in the spleen and liver, but there are many other macrophages elsewhere. 4 This understanding of the mechanism of ITP underlies the major principles of the treatment of the disease: the inhibition of autoantibody for mation; removal of the major plateletdestroying organ, the spleen; and interference with the up take of antibodycoated platelets by phagocytic cells. The American Society of Hematology has endorsed guidelines for the treatment of chronic ITP, which make the important point that thera py is not indicated for an asymptomatic patient with a platelet count of 30,000 or more per cubic millimeter unless there are risk factors for bleed ing. 5 Below that level, the standard recommen dations -now more than 10 years old, yet still valuable -include initial treatment with cortico steroids, and if a sustained remission cannot be induced or if intolerability or adverse events occur, the remaining major choices are splenectomy, intravenous IgG therapy, or the use of immuno suppressive drugs. Intravenous administration of antiRh antibodies is also an option in Rhposi tive patients (the antibodycoated erythrocytes compete with antibodycoated platelets in the phagocytic system). There are yet other possibili ties for treatment; none of them have proven effi cacy, but they are worth trying after all else has failed in a patient covered with ecchymoses and petechiae.
Recently, the idea has arisen that clearance of circulating antibodycoated platelets by phagocy tosis is not the only mechanism of thrombocy topenia in patients with ITP. There is also evi dence of impaired platelet production, probably due to an attack by autoantibodies against mega karyocytes in the bone marrow. 6 Indeed, signs of dying megakaryocytes and even megakaryocytes that have undergone phagocytosis have been ob served in bonemarrow specimens from patients with ITP. 7 It may be surprising that plasma levels of thrombopoietin, the principal regulator of platelet production, are usually normal in pa tients with ITP, whereas they are considerably in creased in those with aplastic anemia or other types of thrombocytopenia associated with bone marrow failure. 8 These contrasting findings indi cate that the liver, the principal source of throm bopoietin, is unable to produce sufficient amounts of the growth factor to keep pace with the plate let destruction.
It seems logical, in light of these recent obser vations, to evaluate the efficacy of thrombopoi etin therapy, which is available as a recombinant polypeptide, in patients with ITP in whom con ventional treatment has failed. There are, how ever, major drawbacks to such an investigation: one is the development of fibrosis in the mar row, and the other is the production of antibod ies against the recombinant polypeptide that also neutralize the recipient's native thrombopoietin. The resulting thrombopoietininduced thrombo cytopenia can be severe and was the principal reason for stopping clinical trials of recombinant thrombopoietin. 9 More recently, small molecular mimics of thrombopoietin, which act as agonists when they bind to the thrombopoietin receptor on mega karyocytes yet have no sequences in common with the native growth factor, have been devel oped. One of these agonists, AMG 513, is a "peptibody" that consists of a pair of identical short peptides, each linked to the Fc region of IgG, which acts as a carrier. Its halflife in hu mans is more than 4 days, and it increases the platelet count in normal volunteers. In a phase 1 study of AMG 513 in 28 patients with chronic ITP who did not have a response to at least one previous type of treatment, the platelet count rose to more than 50,000 per cubic millimeter in 17. The durability of the response and the longterm safety of this peptide mimic are unknown. 10 In this issue of the Journal, Bussel et al. report on the clinical activity of another mimic, eltrom bopag -a simple chain of four carbonbased rings with various side chains. 11 This agonist binds to the thrombopoietin receptor at a point different from the binding site of thrombopoi etin, stimulates the growth of thrombopoietin dependent cell lines in vitro, and raises the plate let count in normal volunteers. In this phase 1 trial of eltrombopag in patients with chronic ITP who did not have a response to at least one pre vious type of treatment, the drug raised the plate let count to 50,000 or more per cubic millimeter in 21 of 26 patients who received 75 mg per day, in 19 of 27 who received 50 mg per day, and in 8 of 29 who received 30 mg per day. As with AMG 531, the durability of the response and the longterm safety of the compound are unknown. In a companion paper in this issue of the Journal, McHutchison et al. report their results regarding eltrombopag in the treatment of thrombocyto penia associated with cirrhosis due to hepatitis C infection. 12 In this small trial, treatment with eltrombopag raised the platelet count to 100,000 or more per cubic millimeter in most patients who received the highest dose of the compound, thereby enabling the initiation of antiviral ther apy. Notably, during the 12week period of anti viral treatment, platelet counts fell despite the con tinuation of eltrombopag therapy, but the levels remained above the baseline. Whether this obser vation has implications for the durability of the response to eltrombopag in patients with ITP is not known.
The results reported for thrombopoietinrecep tor agonists are too preliminary for any definitive statement about applications in clinical practice, but they surely encourage further work in this direction. Hematologists everywhere are thwart ed by patients with ITP in whom every available treatment has failed to improve the platelet count.
A new, safe way of treating the disease would be a considerable advance. 
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8. are one of the few classes of drugs that are em bedded in clinicalperformance measures for cor onary artery disease, which indicates that clini cians should be considered remiss if they do not prescribe these agents for all their eligible pa tients. 3 In the context of the strong evidence base and recommendations supporting the use of statins for secondary prevention of cardiovascular dis ease, in this issue of the Journal Kjekshus et al. 4
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Statins for Ischemic Systolic Heart Failure
